XINGANJIANG
873167
Sichuan Goldstone
300434
Hangzhou Huasu Technology
301157
Suzhou Harmontronics Automation Technology
688022
Xinjiang Tianshan Animal Husbandry Bio-engineering
300313
CN Stock MarketDetailed Quotes
300109 Boai NKY Medical
- 14.35
- -0.08-0.55%
Market Closed Jan 6 15:00 CST
6.96BMarket Cap17.42P/E (TTM)
14.65High14.19Low85.53KlotVolume14.41Open14.43Pre Close123.12MTurnover1.91%Turnover Ratio14.11P/E (Static)484.70MShares18.9852wk High1.98P/B6.43BFloat Cap7.3552wk Low17.32Limit Up448.34MShs Float59.97Historical High11.54Limit Down3.19%Amplitude1.44Historical Low0.67Dividend TTM14.39Avg Price41.33KlotAsk4.65%Div YieldTTM100Lot Size39.10KlotBid
Boai NKY Medical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -7.92%1.11B | -5.68%734.8M | 8.73%394.69M | 6.58%1.58B | 7.12%1.21B | 14.83%779.01M | 16.77%363M | 21.75%1.49B | 30.14%1.13B | 26.48%678.43M |
| Operating revenue | -7.92%1.11B | -5.68%734.8M | 8.73%394.69M | 6.58%1.58B | 7.12%1.21B | 14.83%779.01M | 16.77%363M | 21.75%1.49B | 30.14%1.13B | 26.48%678.43M |
| Other operating revenue | ---- | -54.46%2.63M | ---- | -42.91%20.93M | ---- | 260.20%5.78M | ---- | 53.14%36.66M | ---- | -73.28%1.6M |
| Total operating cost | 5.92%723.05M | 4.89%465.72M | 17.00%243.19M | -2.23%993.25M | -6.97%682.64M | -4.41%444.01M | -11.78%207.85M | -4.23%1.02B | -2.39%733.82M | 1.21%464.52M |
| Operating cost | 10.05%532.12M | 2.15%329.61M | 21.75%183.57M | -13.34%689.03M | -14.40%483.52M | -11.44%322.69M | -18.41%150.78M | 9.30%795.06M | 20.11%564.83M | 27.62%364.39M |
| Operating tax surcharges | 23.63%12M | 88.73%8.83M | 89.75%4.41M | 45.53%13.97M | 37.48%9.71M | 22.91%4.68M | 8.96%2.33M | -16.17%9.6M | -0.25%7.06M | -18.74%3.81M |
| Operating expense | -20.41%39.45M | -17.22%26.72M | -19.78%12.1M | 3.60%67.55M | -12.46%49.57M | 1.79%32.28M | -2.37%15.08M | -9.32%65.2M | -6.70%56.62M | -3.84%31.72M |
| Administration expense | -7.40%107.87M | -5.71%71.75M | 8.19%32.29M | 36.95%168.21M | 21.96%116.49M | 25.99%76.1M | 6.18%29.85M | -32.34%122.83M | -23.34%95.51M | -18.72%60.4M |
| Financial expense | 35.98%-9.79M | 53.76%-7.15M | -122.15%-2.85M | 78.33%-9.21M | 54.31%-15.29M | 20.32%-15.46M | 77.27%-1.28M | -501.05%-42.48M | -204.37%-33.47M | -186.42%-19.4M |
| -Interest expense (Financial expense) | 15.15%3.5M | 23.94%2.43M | 20.76%1.13M | -21.03%2.07M | 17.57%3.04M | 25.84%1.96M | 31.70%934.31K | -93.06%2.62M | -91.24%2.59M | -92.13%1.56M |
| -Interest Income (Financial expense) | 25.94%-8.96M | 12.16%-7.34M | 13.56%-3.82M | 42.23%-13.59M | 40.53%-12.1M | 44.48%-8.36M | 42.09%-4.42M | 51.39%-23.53M | -1,120.09%-20.34M | -954.68%-15.05M |
| Research and development | 7.12%41.4M | 51.51%35.95M | 23.08%13.66M | -3.08%63.71M | -10.68%38.65M | 0.49%23.73M | 3.34%11.1M | -12.98%65.73M | -24.25%43.27M | -39.46%23.61M |
| Credit Impairment Loss | -37.63%-13.05M | -17.67%-9.02M | -191.02%-3.2M | 76.25%-12.05M | 38.79%-9.48M | 26.02%-7.67M | 83.22%-1.1M | -211.23%-50.73M | -73.05%-15.49M | -183.28%-10.37M |
| Asset Impairment Loss | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 99.95%-36.48K | ---- | ---- |
| Other net revenue | -236.60%-22.5M | -436.38%-13.21M | -1,797.07%-8.15M | 93.92%-4.93M | 83.03%-6.69M | 91.79%-2.46M | 98.62%-429.87K | -164.39%-81.09M | -342.91%-39.4M | -191.54%-29.99M |
| Fair value change income | -312.28%-10.63M | -699.14%-5.6M | -468.32%-6.34M | 106.23%2.2M | 90.80%-2.58M | 103.66%935.07K | 95.68%-1.12M | -341.19%-35.33M | -289.59%-28.03M | -197.66%-25.56M |
| Invest income | -452.88%-7.6M | -382.78%-4.74M | ---- | -30.67%-3.27M | 0.05%-1.37M | -141.19%-982.35K | -467.71%-1.37M | -101.33%-2.5M | -119.65%-1.38M | -105.43%-407.29K |
| -Including: Investment income associates | ---- | ---- | ---- | ---- | 69.00%-392.28K | ---- | 20.77%-392.28K | 51.50%-2.03M | 15.80%-1.27M | ---- |
| Asset deal income | 245.91%81.52K | 153.03%11.63K | -542.19%-4.98K | 105.12%44.36K | 163.96%23.57K | -131.12%-21.93K | --1.13K | -87.60%-865.67K | -118.77%-36.84K | -64.10%70.48K |
| Other revenue | 29.27%8.69M | 16.56%6.15M | -56.04%1.39M | -2.78%8.14M | 21.48%6.72M | -15.90%5.27M | 295.35%3.16M | 17.20%8.38M | 72.23%5.54M | 154.12%6.27M |
| Operating profit | -29.34%365.44M | -23.05%255.88M | -7.36%143.35M | 50.57%585.24M | 46.48%517.21M | 80.80%332.54M | 250.89%154.73M | 36.16%388.67M | 171.93%353.1M | 66.91%183.92M |
| Add:Non operating Income | -4.20%2.08M | 58.50%1.21M | -81.42%132.75K | -29.52%1.24M | 73.92%2.17M | 152.22%764.33K | -60.17%714.64K | -58.30%1.76M | -77.37%1.25M | -81.17%303.04K |
| Less:Non operating expense | 1,196.82%6.16M | 1,400.04%4.23M | 892.94%583.06K | -43.16%1.12M | -41.80%474.82K | -59.51%281.98K | -88.31%58.72K | 24.41%1.97M | -56.89%815.86K | 5.76%696.48K |
| Total profit | -30.36%361.36M | -24.07%252.86M | -8.04%142.9M | 50.68%585.36M | 46.78%518.9M | 81.45%333.02M | 242.35%155.38M | 34.84%388.47M | 164.90%353.53M | 65.13%183.53M |
| Less:Income tax cost | -57.88%49.38M | -46.72%39.27M | -39.09%21.97M | -6.97%99.57M | 47.95%117.24M | 81.59%73.7M | 160.75%36.07M | 14.76%107.04M | 109.20%79.25M | 32.68%40.59M |
| Net profit | -22.33%311.98M | -17.63%213.59M | 1.35%120.92M | 72.61%485.79M | 46.44%401.66M | 81.41%259.31M | 278.12%119.31M | 44.46%281.43M | 186.97%274.28M | 77.46%142.94M |
| Net profit from continuing operation | -22.33%311.98M | -17.63%213.59M | 1.35%120.92M | 72.61%485.79M | 46.44%401.66M | 81.41%259.31M | 278.12%119.31M | 44.46%281.43M | 186.97%274.28M | 77.46%142.94M |
| Less:Minority Profit | 122.56%736.19K | 122.71%656.78K | 30.58%-462.43K | 27.80%-7.24M | -0.11%-3.26M | 8.66%-2.89M | 36.60%-666.15K | 17.94%-10.03M | 27.45%-3.26M | -8.57%-3.17M |
| Net profit of parent company owners | -23.13%311.24M | -18.79%212.93M | 1.17%121.39M | 69.16%493.03M | 45.90%404.92M | 79.46%262.21M | 267.98%119.98M | 40.77%291.46M | 177.34%277.54M | 75.05%146.11M |
| Earning per share | ||||||||||
| Basic earning per share | -22.35%0.66 | -18.18%0.45 | -2.56%0.38 | 80.68%1.59 | 0.00%0.85 | 25.00%0.55 | 290.00%0.39 | 37.50%0.88 | 183.33%0.85 | 69.23%0.44 |
| Diluted earning per share | -21.69%0.65 | -18.52%0.44 | 2.70%0.38 | 78.82%1.52 | -2.35%0.83 | 22.73%0.54 | 311.11%0.37 | 37.10%0.85 | 183.33%0.85 | 69.23%0.44 |
| Other composite income | -102.31%-41.66K | -211.13%-172.64K | -130.98%-2.8M | -85.07%1.81M | -17.07%155.34K | 1,009.34%9.04M | 1,169.59%12.1M | 777.29%10.42M | ||
| Other composite income of parent company owners | -102.31%-41.66K | ---- | -211.13%-172.64K | -130.98%-2.8M | -85.07%1.81M | ---- | -17.07%155.34K | 1,009.34%9.04M | 1,169.59%12.1M | 777.29%10.42M |
| Total composite income | -22.68%311.94M | -17.63%213.59M | 1.07%120.75M | 66.28%482.99M | 40.88%403.46M | 69.08%259.31M | 276.38%119.47M | 49.86%290.47M | 203.21%286.38M | 94.11%153.37M |
| Total composite income of parent company owners | -23.49%311.2M | -18.79%212.93M | 0.90%121.21M | 63.14%490.23M | 40.42%406.73M | 67.51%262.21M | 266.35%120.14M | 45.84%300.5M | 192.74%289.64M | 91.06%156.53M |
| Total composite income of minority owners | 122.56%736.19K | 122.71%656.78K | 30.58%-462.43K | 27.80%-7.24M | -0.11%-3.26M | 8.66%-2.89M | 36.60%-666.15K | 17.94%-10.03M | 27.45%-3.26M | -8.57%-3.17M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Zhongqin Wanxin Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Zhongqin Wanxin Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
